Cutting-edge artificial intelligence, particularly large language models (LLMs), are reshaping drug discovery and development processes. These advanced AI architectures accelerate molecule design, target identification, and data analysis, redefining pharmaceutical R&D workflows. By transitioning from mere computational tools to collaborative partners, LLMs are driving efficiency gains and unlocking novel therapeutic possibilities within medicine.